U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07230132) titled 'Efficacy and Safety of ZT006 in Overweight and Obese Participants' on Nov. 13.
Brief Summary: This study is being conducted to evaluate the efficacy and safety of ZT006 tablet in participants with overweight and obesity.
In addition to dietary caloric restriction and increased physical activity, study participants will receive either ZT006 tablets or placebo tablets once every morning (placebo looks like ZT006 tablets but has no active pharmaceutical ingredients). For a fair comparison, study participants are assigned to ZT006 or placebo randomly by a computer.
The treatment will last for 28 weeks. ZT006 tablets will be administer...